Journal article
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)‐1 or PD ligand 1 inhibitor therapy
Abstract
OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors.
PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were …
Authors
Sonpavde G; Pond GR; Mullane S; Ramirez AA; Vogelzang NJ; Necchi A; Powles T; Bellmunt J
Journal
BJU International, Vol. 119, No. 4, pp. 579–584
Publisher
Wiley
Publication Date
April 2017
DOI
10.1111/bju.13674
ISSN
1464-4096
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCarcinoma, Transitional CellDrug Administration ScheduleFemaleHumansImmunotherapyMaleMiddle AgedMolecular Targeted TherapyProgrammed Cell Death 1 ReceptorRetrospective StudiesUrologic Neoplasms